CCR 20th Anniversary Commentary: Stayin' Alive-Antiapoptotic Proteins and Breast Cancer

被引：0
作者：
Yee, Douglas [1 ]
机构：
[1] Univ Minnesota, Mason Canc Ctr, Dept Med, Minneapolis, MN 55455 USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 04期
关键词：
SURVIVIN ANTISENSE OLIGONUCLEOTIDE; CELL LUNG-CANCER; TARGETING SURVIVIN; PHASE; SUPPRESSOR; APOPTOSIS; LY2181308; YM155;
D O I：
10.1158/1078-0432.CCR-14-2548
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The control of cell death involves a complex interaction of multiple proteins. In a study published in the January 1, 2000, issue of Clinical Cancer Research, Tanaka and colleagues demonstrated that one of the proapoptotic proteins, survivin, was frequently expressed in breast cancer. In the subsequent years, effectors of apoptosis have translated into important prognostic indicators and potential therapeutic targets. - © 2015 American Association for Cancer Research.
引用
收藏
页码：665 / 666
页数：2
相关论文
共 11 条
[1]   Targeting survivin in cancer [J].
Altieri, Dario C. .
CANCER LETTERS, 2013, 332 (02) :225-228
[2]   Treatment of HER2-positive breast cancer: current status and future perspectives [J].
Arteaga, Carlos L. ;
Sliwkowski, Mark X. ;
Osborne, C. Kent ;
Perez, Edith A. ;
Puglisi, Fabio ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (01) :16-32
[3]   Treat cancers by targeting survivin: Just a dream or future reality? [J].
Coumar, Mohane Selvaraj ;
Tsai, Fang-Ying ;
Kanwar, Jagat Rakesh ;
Sarvagalla, Sailu ;
Cheung, Chun Hei Antonio .
CANCER TREATMENT REVIEWS, 2013, 39 (07) :802-811
[4]   A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer [J].
Kelly, R. J. ;
Thomas, A. ;
Rajan, A. ;
Chun, G. ;
Lopez-Chavez, A. ;
Szabo, E. ;
Spencer, S. ;
Carter, C. A. ;
Guha, U. ;
Khozin, S. ;
Poondru, S. ;
Van Sant, C. ;
Keating, A. ;
Steinberg, S. M. ;
Figg, W. ;
Giaccone, G. .
ANNALS OF ONCOLOGY, 2013, 24 (10) :2601-2606
[5]   APOPTOSIS - BASIC BIOLOGICAL PHENOMENON WITH WIDE-RANGING IMPLICATIONS IN TISSUE KINETICS [J].
KERR, JFR ;
WYLLIE, AH ;
CURRIE, AR .
BRITISH JOURNAL OF CANCER, 1972, 26 (04) :239-+
[6]   A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma [J].
Lewis, Karl D. ;
Samlowski, Wolfram ;
Ward, John ;
Catlett, Joseph ;
Cranmer, Lee ;
Kirkwood, John ;
Lawson, David ;
Whitman, Eric ;
Gonzalez, Rene .
INVESTIGATIONAL NEW DRUGS, 2011, 29 (01) :161-166
[7]   Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non-Small-Cell Lung Cancer A Randomized Open-Label Phase II Study [J].
Natale, Ronald ;
Blackhall, Fiona ;
Kowalski, Dariusz ;
Ramlau, Rodryg ;
Bepler, Gerold ;
Grossi, Francesco ;
Lerchenmueller, Christian ;
Pinder-Schenck, Mary ;
Mezger, Joerg ;
Danson, Sarah ;
Gadgeel, Shirish M. ;
Summers, Yvonne ;
Callies, Sophie ;
Andre, Valerie ;
Das, Mayukh ;
Lahn, Michael ;
Talbot, Denis .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) :1704-1708
[8]   A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J].
Paik, S ;
Shak, S ;
Tang, G ;
Kim, C ;
Baker, J ;
Cronin, M ;
Baehner, FL ;
Walker, MG ;
Watson, D ;
Park, T ;
Hiller, W ;
Fisher, ER ;
Wickerham, DL ;
Bryant, J ;
Wolmark, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2817-2826
[9]  
Tanaka K, 2000, CLIN CANCER RES, V6, P127
[10]   S-phase fraction and breast cancer - a decade of experience [J].
Wenger, CR ;
Clark, GM .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 51 (03) :255-265
12